[an error occurred while processing this directive]

HEREDITAS ›› 2013, Vol. 35 ›› Issue (11): 1244-1252.doi: 10.3724/SP.J.1005.2013.01244

Previous Articles     Next Articles

The function and application of the IL28B gene in HCV infection and treatment

MA Ke, ZHANG A-Mei, XIA Xue-Shan   

  1. Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China
  • Received:2013-06-09 Revised:2013-07-26 Online:2013-11-20 Published:2013-10-25

Abstract:

Hepatitis C virus (HCV) is the etiological factor for Hepatitis C, which is one of the most important pathogenic factors of chronic liver diseases, cirrhosis and even hepatocellular carcinoma. HCV infection brings great threat to human health. Host genetic background could impact HCV infection, viral clearance, and treatment. Recently, some genome-wide association studies (GWAS) of HCV patients were performed. The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-λ3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNα combined with ribavirin (RBV). IFN-λ3 interacts with its acceptor, a heterodimer (IFN-λR1•IL-10R2), and upregulates the IFN-stimulated gene factors (ISGF). IFN-λ3 plays roles in antiviral, antitumor, and immunoloregulation, and thus it might become a potential drug for Hepatitis C treatment. However, the mechanism of the IL28B gene in HCV infection and treatment is unclear, and further studies are needed to reveal the veils and provide theoretical basis for developing a new antiviral drug in clinic.

Key words: hepatitis C, the IL28B gene, response to treatment, viral clearance